A PHASE 3, INTERVENTIONAL, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY OF DCC-2618 VS SUNITINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS AFTER TREATMENT WITH IMATINIB
- Registry ID
- DCC-2618-03-002 (INTRIGUE)
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- DECIPHERA PHARMACEUTICALS. LLC
- Start date
- 2020-09-24
- Last update
- 2018-10-18
Conditions
- GASTROINTESTINAL STROMAL TUMOR (GIST)
Related clinical trials
- A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY OF IDRX-42 (GSK6042981) VERSUS SUNITINIB IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST) AFTER IMATINIB THERAPY (STRATEGIST 3)
- AN INTERNATIONAL, PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY OF RIPRETINIB VS SUNITINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST) WITH KIT EXON 11 AND CO-OCCURRING KIT EXONS 17 AND/OR 18 MUTATIONS WHO WERE PREVIOUSLY TREATED WITH IMATINIB (INSIGHT)
- (PEAK) A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC GASTROINTESTINAL STROMAL TUMORS
- A PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BELZUTIFAN (MK-6482, FORMERLY PT2977) MONOTHERAPY IN PARTICIPANTS WITH ADVANCED PHEOCHROMOCYTOMA/PARAGANGLIOMA (PPGL), PANCREATIC NEUROENDOCRINE TUMOR (PNET), VON HIPPEL-LINDAU (VHL) DISEASE-ASSOCIATED TUMORS, ADVANCED GASTROINTESTINAL STROMAL TUMOR (WT GIST), OR ADVANCED SOLID TUMORS WITH HIF-2A RELATED GENETIC ALTERATIONS
View on source registry